

CERTIFICATE OF FACSIMILE/ELECTRONIC TRANSMISSION

I hereby certify that this paper is being facsimile/electronically transmitted to the Patent and Trademark Office on the date shown below.

May 30, 2007

Date

Marlene Capreri

Signature of certifier

Marlene Capreri

Typed or printed name of certifier

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Patent Application of Peters Kempers. et al.	:	Group Art Unit: 1623
		:	
Appln. No.	10/595,656	:	Examiner: Unknown
		:	
Filed:	January 3, 2007	:	Confirmation No. 4227
		:	
For:	ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES, COMPOSI- TIONS OF, AND METHODS OF MAKING THEREOF	:	Attorney Docket No. C 2903 PCT/US
		:	Customer No. 23657

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We hereby request the following correction of the Filing Receipt for Serial No.: 10/595,656.

The Title for the above-referenced application should be corrected to read:

Acyl ribonucleosides and acyl Acyl deoxyribonucleosides, ~~compositions~~ Compositions of,  
and ~~methods~~ Methods of making ~~same~~ Making Thereof

Thank you for your assistance in this matter.

May 30, 2007

Date

Respectfully submitted,

Cognis Corporation  
300 Brookside Avenue  
Ambler, PA 19002

John F. Daniels  
John F. Daniels  
(Reg. No. 34,314)  
Attorney for Applicants  
215-628-1413

Enc.: (1) Filing Receipt (true copy showing change)  
(2) First page of Marked-Up Spec (copy)(showing correction to title of I.A.)  
(3) First page of Substitute Spec (copy)(showing title)

JFD/ME



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL. NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
10/595,656	01/03/2007	1623	1030	C 2903 PCT/US	8	2

23657  
COGNIS CORPORATION  
PATENT DEPARTMENT  
300 BROOKSIDE AVENUE  
AMBLER, PA 19002

CONFIRMATION NO. 4227 ✓

FILING RECEIPT



\*OC00000023213264\*

Date Mailed: 04/04/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter Kempers, Grevenbroich, GERMANY;  
Philippe Moussou, Nancy, FRANCE;  
Louis Danoux, Saulxures Les Nancy, FRANCE;  
Sabine Both, Duesseldorf, GERMANY;  
Carsten Beverungen, Duesseldorf, GERMANY;

Assignment For Published Patent Application

COGNIS IP MANAGEMENT GMBH, Dusseldorf, GERMANY  
COGNIS FRANCE S.A., Saint-Martory, FRANCE

Power of Attorney: The patent practitioners associated with Customer Number 23657.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/11990 10/23/2004

RECEIVED COGNIS LAW DEPT.  
ACTION \_\_\_\_\_ INFO \_\_\_\_\_

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 03292735.2 11/03/2003

APR 09 2007

DUE \_\_\_\_\_  
FILE C 2903 PCT/US

If Required, Foreign Filing License Granted: 03/31/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/595,656**

ENTERED  
WINPAT DATABASE

**Projected Publication Date:** 07/12/2007

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Acyl ribonucleosides and <sup>A</sup>acyl deoxyribonucleosides, <sup>C</sup>compositions of, and <sup>M</sup>methods of <sup>M</sup>making  
~~same~~ ~~Thereof~~

**Preliminary Class**

514

## **PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PATENT****CASE NO.: C 2903 PCT/US****Title****5     Acyl ribonucleosides and Acyl deoxyribonucleosides, Compositions of, and Methods of Making Thereof****Related Applications**

10     This national phase application is filed under 35 U.S.C. § 371 from International Application No. PCT/EP2004/011990 filed October 23, 2004, which designated the United States of America and which claims priority from European application EP 03292735.2 filed November 3, 2003; the entire contents of each application are hereby incorporated herein by reference.

**15     Field of the Invention**

The present invention is ~~concerned with~~ directed to acyl ribonucleosides and with acyl deoxyribonucleosides. It is furthermore ~~concerned with~~ directed to an enzymatic process for the manufacture of acyl ribonucleosides and of acyl deoxyribonucleosides. It is furthermore ~~concerned with~~ directed to the use of acyl ribonucleosides and of acyl deoxyribonucleosides for cosmetic and for pharmaceutical purposes and with their use as a food supplement for humans or animals. It is furthermore ~~concerned with~~ directed to compositions containing acyl ribonucleosides and acyl deoxyribonucleosides, whereby these compositions are suitable for cosmetic purposes.

**25     Background of the Invention**

Ribonucleosides are known compounds in which a nucleobase is linked to the sugar D-ribose. In deoxyribonucleosides a nucleobase is linked to the sugar 2-desoxy-D-ribose. Nucleobases are in particular uracil, cytosine, thymine, adenine and guanine. The name of

**SUBSTITUTE SPECIFICATION****PATENT****CASE NO.: C 2903 PCT/US****Title****5     Acyl ribonucleosides and Acyl deoxyribonucleosides, Compositions of, and Methods  
          of Making Thereof****Related Applications**

10     This national phase application is filed under 35 U.S.C. § 371 from International  
Application No. PCT/EP2004/011990 filed October 23, 2004, which designated the  
United States of America and which claims priority from European application EP  
03292735.2 filed November 3, 2003; the entire contents of each application are hereby  
incorporated herein by reference.

**15     Field of the Invention**

The present invention is directed to acyl ribonucleosides and with acyl  
deoxyribonucleosides. It is furthermore directed to an enzymatic process for the  
manufacture of acyl ribonucleosides and of acyl deoxyribonucleosides. It is furthermore  
directed to the use of acyl ribonucleosides and of acyl deoxyribonucleosides for cosmetic  
20     and for pharmaceutical purposes and with their use as a food supplement for humans or  
animals. It is furthermore directed to compositions containing acyl ribonucleosides and  
acyl deoxyribonucleosides, whereby these compositions are suitable for cosmetic  
purposes.

**25     Background of the Invention**

Ribonucleosides are known compounds in which a nucleobase is linked to the sugar D-  
ribose. In deoxyribonucleosides a nucleobase is linked to the sugar 2-desoxy-D-ribose.  
Nucleobases are in particular uracil, cytosine, thymine, adenine and guanine. The name of